Abdou Hassan Wael, Shalaby Essam, Abo-Hashesh Mona, Ibrahim Ali Rehab
Department of Basic Sciences, College of Medicine, Suliman Al Rajhi University, Al Bukayriyah, Kingdom of Saudi Arabia.
Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Res Rep Urol. 2021 May 5;13:197-206. doi: 10.2147/RRU.S296974. eCollection 2021.
The roles of c-KIT and HER2 protein expression in bladder cancer are still debated, and the prognostic value of these proteins as markers of tumor progression is inconclusive.
To assess the impact of HER2 and c-KIT protein expressions in the progression of non-muscle-invasive bladder cancer.
All patients undergoing transurethral resection of bladder tumors for non-muscle-invasive urothelial carcinoma, with standard regimen of BCG, between January 2017 and November 2019, were evaluated pathologically and immunohistochemically for HER1 and c-KIT proteins in urothelial carcinoma cells. Follow-up cystoscopy was performed for 100 patients every 3 months for the first 2-years and any recurred tumors were excised and examined pathologically, as well as stained for HER2 and c-KIT protein expression.
HER2 and c-KIT positive expressions were detected in 49% and 38% of cases, respectively. After a mean follow-up of 26.4±7.2 months, the overall recurrence and progression rates were significantly correlated with overexpression of HER2 and c-KIT. In high-grade non-invasive muscle neoplasms, tumor cells showed weak expression for both HER2 and c-KIT proteins, but with progression to muscle-invasion, tumor cells strongly expressed HER2 and lost expression to c-KIT. In the multivariate model, overexpression of HER2 rather than c-KIT protein significantly predicted increased progression.
Recurrence and progression of non-muscle-invasive bladder cancer correlate with overexpression of HER2 and c-KIT proteins in tumor cells.
c-KIT和HER2蛋白表达在膀胱癌中的作用仍存在争议，这些蛋白作为肿瘤进展标志物的预后价值尚无定论。
评估HER2和c-KIT蛋白表达对非肌层浸润性膀胱癌进展的影响。
对2017年1月至2019年11月期间接受经尿道膀胱肿瘤切除术治疗非肌层浸润性尿路上皮癌且采用卡介苗标准治疗方案的所有患者，对尿路上皮癌细胞中的HER1和c-KIT蛋白进行病理和免疫组化评估。对100例患者在最初2年每3个月进行一次随访膀胱镜检查，任何复发肿瘤均切除并进行病理检查，同时进行HER2和c-KIT蛋白表达染色。
分别在49%和38%的病例中检测到HER2和c-KIT阳性表达。平均随访26.4±7.2个月后，总体复发率和进展率与HER2和c-KIT的过表达显著相关。在高级别非浸润性肌肉肿瘤中，肿瘤细胞HER2和c-KIT蛋白均呈弱表达，但随着进展至肌肉浸润，肿瘤细胞HER2强表达而c-KIT表达缺失。在多变量模型中，HER2而非c-KIT蛋白的过表达显著预测进展增加。
非肌层浸润性膀胱癌的复发和进展与肿瘤细胞中HER2和c-KIT蛋白的过表达相关。
